These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32388534)

  • 1. Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.
    Li H; Yin L; Wang Y; Wang X; Shi M; Cao J; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
    Bone Marrow Transplant; 2020 Nov; 55(11):2215-2218. PubMed ID: 32388534
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma-A Call for Equal Opportunity.
    Goldfinger M; Shah N; Cooper DL
    JAMA Oncol; 2023 Mar; 9(3):297-298. PubMed ID: 36602789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma.
    Giri S; Bal S; Godby KN; Ravi G; Clark D; Ubersax C; Cooley A; White P; Rangarajan S; Williams GR; Costa LJ
    Am J Hematol; 2022 Apr; 97(4):E153-E155. PubMed ID: 35045201
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.
    Gagelmann N; Ayuk FA; Klyuchnikov E; Wolschke C; Berger SC; Kröger N
    Haematologica; 2023 Oct; 108(10):2799-2802. PubMed ID: 36815380
    [No Abstract]   [Full Text] [Related]  

  • 5. Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma.
    Bal S; Costa LJ
    Br J Haematol; 2024 Feb; 204(2):449-454. PubMed ID: 38036424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
    Hosen N
    Rinsho Ketsueki; 2018; 59(10):2189-2194. PubMed ID: 30305525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.
    Gurney M; Baranwal A; Rosenthal A; Kharfan-Dabaja MA; Kenderian SS; Lin Y; Shah MV
    JAMA Oncol; 2024 Apr; 10(4):532-535. PubMed ID: 38386311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
    Hosen N
    Rinsho Ketsueki; 2021; 62(6):619-623. PubMed ID: 34219089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chimeric antigen receptor T cells: the challenge to current treatment of multiple myeloma].
    Fu CC
    Zhonghua Nei Ke Za Zhi; 2020 Jul; 59(7):495-497. PubMed ID: 32594682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.
    Mohyuddin GR; Rooney A; Balmaceda N; Aziz M; Sborov DW; McClune B; Kumar SK
    Blood Adv; 2021 Feb; 5(4):1097-1101. PubMed ID: 33606005
    [No Abstract]   [Full Text] [Related]  

  • 13. [New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma-Review].
    Zhang FR; Li X; Liu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1316-1320. PubMed ID: 31418399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
    Al Hadidi S; Zangari M; van Rhee F
    JAMA Oncol; 2022 Jun; 8(6):823-824. PubMed ID: 35482363
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hematological toxicity and risk factors in relapsed/refractory multiple myeloma patients after CAR-T therapy].
    Zhao TT; Ge J; Zhu H; Ma RB; Li CY; Wan CY; Wang Y; Xu KL; Li ZY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):858-860. PubMed ID: 36709201
    [No Abstract]   [Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.
    Wang B; Rajeeve S; Madduri D
    Cancer J; 2021 May-Jun 01; 27(3):205-212. PubMed ID: 34549909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
    Cohen AD
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
    [No Abstract]   [Full Text] [Related]  

  • 19. Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma.
    Friend R; Atrash S
    Transplant Cell Ther; 2024 Mar; 30(3):253-254. PubMed ID: 38485337
    [No Abstract]   [Full Text] [Related]  

  • 20. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
    Kagoya Y
    Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.